Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

by De Lima Lopes Jr., G., Segel, J.E., Tan, D.S.W., Do, Y.K., Mok, T., Finkelstein, E.A.
Published 2016

Obtaining spatially resolved tumor purity maps using deep multiple instance learning in a pan-cancer study

by Oner, MU, Chen, J, Revkov, E, James, A, Heng, SY, Kaya, AN, Alvarez, JJS, Takano, A, Cheng, XM, Lim, TKH, Tan, DSW, Zhai, W, Skanderup, AJ, Sung, WK, Lee, HK
Published 2022

Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer

by Tan, D.S.W, Haaland, B, Gan, J.M, Tham, S.C, Sinha, I, Tan, E.H, Lim, K.H, Takano, A, Krisna, S.S, Thu, M.M.M, Liew, H.P, Ullrich, A, Lim, W.-T, Chua, B.T
Published 2020

Lipidomic Profiling of Lung Pleural Effusion Identifies Unique Metabotype for EGFR Mutants in Non-Small Cell Lung Cancer

by Ho, Y.S, Yip, L.Y, Basri, N, Chong, V.S.H, Teo, C.C, Tan, E, Lim, K.L, Tan, G.S, Yang, X, Yeo, S.Y, Koh, M.S.Y, Devanand, A, Takano, A, Tan, E.H, Tan, D.S.W, Lim, T.K.H
Published 2020

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by...

by Park, Keunchil, Vansteenkiste, J., Lee, K.H., Pentheroudakis, G., Zhou, C., Prabhash, K., Seto, T., Voon, P.J., Tan, D.S.W., Yang, J.C.H., Wang, J., Babu, K. Govind, Nakayama, Y., Alip, Adlinda, Chua, K.L.M., Cheng, J.C.-H., Senan, S., Ahn, Y.C., Kim, T.-Y., Ahn, H.K., Peters, S., Yoshino, T., Douillard, J.-Y.
Published 2020

Human Tumor-Infiltrating MAIT Cells Display Hallmarks of Bacterial Antigen Recognition in Colorectal Cancer

by Li, S., Simoni, Y., Becht, E., Loh, C.Y., Li, N., Lachance, D., Koo, S.-L., Lim, T.P., Tan, E.K.W., Mathew, R., Nguyen, A., Golovato, J., Berkson, J.D., Prlic, M., Lee, B., Minot, S.S., Nagarajan, N., Dey, N., Tan, D.S.W., Tan, I.B., Newell, E.W.
Published 2021

Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance

by Vettore A.L., Ramnarayanan K., Poore G., Lim K., Ong C.K., Huang K.K., Leong H.S., Chong F.T., Lim T.K.-H., Lim W.K., Cutcutache I., Mcpherson J.R., Suzuki Y., Zhang S., Skanthakumar T., Wang W., Tan D.S.W., Cho B.C., Teh B.T., Rozen S., Tan P., Iyer N.G.
Published 2018

A three gene immunohistochemical panel serves as an adjunct to clinical staging of patients with head and neck cancer

by Ong C.-A.J., Shannon N.B., Mueller S., Lek S.M., Qiu X., Chong F.T., Li K., Koh K.K.N., Tay G.C.A., Skanthakumar T., Hwang J.S.G., Lim T.K.H., Ang M.K., Tan D.S.W., Tan N.-C., Tan H.K., Soo K.C., Iyer N.G.
Published 2020

Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time

by Chia, S, Low, J.-L, Zhang, X, Kwang, X.-L, Chong, F.-T, Sharma, A, Bertrand, D, Toh, S.Y, Leong, H.-S, Thangavelu, M.T, Hwang, J.S.G, Lim, K.-H, Skanthakumar, T, Tan, H.-K, Su, Y, Hui Choo, S, Hentze, H, Tan, I.B.H, Lezhava, A, Tan, P, Tan, D.S.W, Periyasamy, G, Koh, J.L.Y, Gopalakrishna Iyer, N, Dasgupta, R
Published 2020

Impact of smoking and brain metastasis on outcomes of advanced EGFR mutation lung adenocarcinoma patients treated with first line epidermal growth factor receptor tyrosine kinase i...

by Jain A., Lim C., Gan E.M., Ng D.Z., Ng Q.S., Ang M.K., Takano A., Chan K.S., Tan W.M., Kanesvaran R., Toh C.K., Loo C.M., Hsu A.A.L., Devanand A., Lim C.H., Koong H.N., Koh T., Fong K.W., Yap S.P., Kim S.W., Chowbay B., Oon L., Lim K.H., Lim W.T., Tan E.H., Tan D.S.W.
Published 2020

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing

by Nahar, R, Zhai, W, Zhang, T, Takano, A, Khng, A.J, Lee, Y.Y, Liu, X, Lim, C.H, Koh, T.P.T, Aung, Z.W, Lim, T.K.H, Veeravalli, L, Yuan, J, Teo, A.S.M, Chan, C.X, Poh, H.M, Chua, I.M.L, Liew, A.A, Lau, D.P.X, Kwang, X.L, Toh, C.K, Lim, W.-T, Lim, B, Tam, W.L, Tan, E.-H, Hillmer, A.M, Tan, D.S.W
Published 2020

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

by Ng, K.P., Hillmer, A.M., Chuah, C.T.H., Juan, W.C., Ko, T.K., Teo, A.S.M., Ariyaratne, P.N., Takahashi, N., Sawada, K., Fei, Y., Soh, S., Lee, W.H., Huang, J.W.J., Allen Jr., J.C., Woo, X.Y., Nagarajan, N., Kumar, V., Thalamuthu, A., Poh, W.T., Ang, A.L., Mya, H.T., How, G.F., Yang, L.Y., Koh, L.P., Chowbay, B., Chang, C.-T., Nadarajan, V.S., Chng, W.J., Than, H., Lim, L.C., Goh, Y.T., Zhang, S., Poh, D., Tan, P., Seet, J.-E., Ang, M.-K., Chau, N.-M., Ng, Q.-S., Tan, D.S.W., Soda, M., Isobe, K., Nöthen, M.M., Wong, T.Y., Shahab, A., Ruan, X., Cacheux-Rataboul, V., Sung, W.-K., Tan, E.H., Yatabe, Y., Mano, H., Soo, R.A., Chin, T.M., Lim, W.-T., Ruan, Y., Ong, S.T.
Published 2014